VENOME SISTHAEMA HEVO T - Venome


VENOME SISTHAEMA HEVO T

Venome SISTHAEMA is a unique aesthetic medicine solution that combines a synergistic action between a filler and a stimulating booster. The composition of the product allows to provide multiple treatment aspects, thanks to its unique ability to activate strong tissue fibroplasia, thus increasing the amount of type III collagen fibers and improving skin hydration by raising GAG levels. Venome Sisthaema is a hydrogel for intradermal injections, with a breakthrough and patented formulation containing 70 mg of active ingredients, such as 50 mg of fragmented hyaluronic acid, and 20 mg of trehalose, with proven longer tissue retention, compared to other stimulant formulations. The product has a Class III medical certificate.

SISTHAEMIC DERMAL REGENERATION

The treatment activates the Sisthaemic Dermal Regeneration process, which involves the tissue fibroplasia activation, the idea of which is to induce targeted division and proliferation of fibroblasts and self-regeneration to increase connective tissue volume. Skin cells produce type III collagen fibers more efficiently, resulting in a natural tissue lifting effect in a way that harmoniously accentuates facial features. The effect of the product is maintained for weeks after treatment and becomes stronger with time.

UNIQUE, PATENTED COMPOSITION

Venome Sisthaema is a unique combination of fragmented hyaluronic acid and trehalose that contributes to skin volumization and deep hydration for up to 5 weeks.

Fragmented hyaluronic acid 50mg

Venome Sisthaema is based on two molecular weights of hyaluronic acid - 1200-1500 kDa and 200-400 kDa. Fragmented high-molecular-weight hyaluronic acid adds volume to tissues by stimulating type III collagen production, and severe water binding in the dermis. The low-molecular-weight acid makes the gel soft and the procedure painless.

Sisthaema's formulation contains hyaluronic acid fragments of the purest, pharmaceutical grade, demonstrating the lowest endotoxin levels, resulting in a formulation that does not cause swelling.

During the production process, hyaluronic acid undergoes fragmentation, that is, shortening the chains into smaller ones. Fragmentation of long linear hyaluronic acid chains into corresponding short elements of strictly defined 28-40 monomer size, allows to effectively stimulate the production of type III collagen (the young collagen), thanks to its ability to activate CD44 receptors on fibroblasts.

Innovative trehalose 20 mg

The trehalose, a disaccharide present in the product, protects the hyaluronic acid structure from enzymatic degradation and oxidation, thus the product can be retained in the skin longer than other formulations based on uncross-linked hyaluronic acid. Trehalose extends the duration of product activity in the dermis, providing a more effective stimulation and rejuvenation process. Trehalose makes the effects of Venome Sisthaema exceptional, as confirmed by clinical trials.

Welcome to the New Era of VENOME SISTHAEMIC DERMAL REGENERATION

SELECTIVE SPECTRUM PRODUCTION TECHNOLOGY

Sisthaema uses a unique Selective Spectrum Technology, an advanced production procedure that identifies ingredients with different molecular weights and spatial arrangements, and then selects those that will most effectively achieve the goal (meaning: tissue fibroplasia and stimulation), and maximize the final product’s effectiveness. SST allows to select acid fragments that have much better aesthetic capabilities.

SCIENTIFICALLY PROVEN PERFORMANCE

The effects of SISTHAEMA HEVO T were analyzed by PET scan, highlighting the physiological effect, with no pathological inflammation associated with product injection in the treated tissues.

A 2 ML PREFILLED SYRINGE CONTAINS:

Uncross-linked hyaluronic acid - 50 mg
Trehalose - 20 mg
Two 30 G needles

Venome SISTHAEMA treatment protocol

Venome SISTHAEMA can be injected using several methods, both linear and mesotherapy techniques, 9-point and TENSE technique, each time to a dermis depth of 1.6-2.0 mm.

SISTHAEMA can be injected into the facial area, as well as the hands and neck, or other parts of the body.

The TENSE technique was developed to enhance the product's lifting and regenerative properties. Tense Technique allows you to create 9 linear vectors.

Vector 1 from the ear cartilage, Vector 2 containing 3 lines from the angle of the jaw, Vector 3 containing 2 lines (a point from the lateral angle of the eye and the ala of the nose), Vector 4 nasolabial folds, Vector 5 marionette line, Vector 6 lower part of the chin. Each vector (point) in the linear retrograde technique leaves deposits of 0.1 mL each, except for vectors 4 and 1, which contain 0.15 mL each.

5-POINT TECHNIQUE

The 5-point technique involves inserting the needle perpendicularly into the deep layers of the dermis, and leaving deposits of 0.1-0.3 mL per point.

The points should be distributed in 5 sites on one side of the face and on the other.

  • Point 1 - 2 cm down from the lateral angle of the palpebral fissure on the line connecting the angle of the mandible
  • Point 2 - 1 cm laterally from the ala of the nose
  • Point 3 - 1 cm in a straight line from the ear cartilage
  • Point 4 - 2 cm downward and 1 cm medially from the line drawn from the lateral angle of the red zone of the lip downward
  • Point 5 - 1.5 cm medially and upward from the angle of the mandible
  • LOSS OF FIRMNESS
  • LACK OF SKIN DENSITY
  • SAGGING CHEEKS
  • LOW TISSUE ELASTICITY
  • LACK OF HYDRATION

Face, neck, décolleté, hands – every 15-30 days in sessions of 4-5 repetitions

VENOME SISTHAEMA must not be used in: 

  • patients who tend to develop hypertrophic scarring, 
  • patients with a history of autoimmune disease or who are receiving immune therapy,
  • patients who are known to be hypersensitive to hyaluronic acid,
  • pregnant or breastfeeding women,
  • patients under 18 years of age.
  • Avoid to use in combination with peeling, laser or ultrasound-based treatment.
  • Patients who are using substances that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may, as with any injection, experience increased bruising or bleeding at treatment sites.
  • Anticoagulated patients or patients receiving platelet aggregation inhibitors should not be treated with VENOME SISTHAEMA without consulting their doctors.
  • VENOME SISTHAEMA must not be used in areas presenting cutaneous, inflammatory and/or infectious processes (e.g. acne, herpes ...). VENOME SISTHAEMA must not be used in association with laser therapy, chemical peeling or dermabrasion.
  • Do not inject into blood vessels. Do not use VENOME SISTHAEMA in bones, tendons, ligaments or muscles. Do not inject VENOME SISTHAEMA into naevi.
  • There are no available clinical data (efficiency, tolerance) about injecting VENOME SISTHAEMA into an area which has already been treated with another filling product.

INTERACTIONS WITH OTHER AGENTS:

  • Inflammatory reactions (e.g. redness, oedema. erythema ...) which may be associated with itching and pain on pressure after the injection. These reactions may last for a week.
  • Indurations or nodules at the injection site especially in cases of too superficial placement.
  • Discolouration of the injection site.